89bio: Undervalued Contender In Race For First NASH Drug Approval
magicmine/iStock via Getty Images
Investment Thesis
89bio (NASDAQ:ETNB) is a $350m market cap biotech developing a single asset – BIO89-100, a specifically engineered glycoPEGylated analog of the fibroblast growth factor FGF21 – as a potential treatment…
